FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229058277> ?p ?o ?g. }

• W4229058277 endingPage "32" @default.
• W4229058277 startingPage "31" @default.
• W4229058277 abstract "In concert with the NIH HEAL Initiative, the NINDS established the Early Phase Pain Investigation Clinical Network (EPPIC-Net) to accelerate clinical trials of non-addictive pharmacologic/non-pharmacologic therapeutics (“assets”) for pain conditions of high unmet need. We present EPPIC-Net's accomplishments since opening in Q4 of 2019. In its first year, EPPIC-Net established a robust infrastructure including a Clinical Coordinating Center, Data Coordinating Center, and 12 Specialized Clinical Centers across the US, providing broad outreach to diverse pain populations. For accepted assets, EPPIC-Net delivers a collaborative network of multi-disciplinary pain experts who provide novel early phase clinical trial design, incorporating proof-of-concept testing and biomarker validation, study conduct, and data analysis. NINDS utilizes a unique, rigorous, 3-stage application/review process, with trials funded under NIH's “Other Transactions” Authority. For accepted assets, trials are run by the NIH-funded network, at no cost to asset providers who provide clinical grade asset for the trial. Asset owners retain intellectual property rights to their asset. In its first two years of operation, EPPIC-Net funded clinical trials for three assets. The first trial, focused on painful knee osteoarthritis, is open to enrollment. Start-up activities are underway for the others. The latter two trials will be conducted under an innovative master platform protocol for painful diabetic peripheral neuropathy. The master protocol will run in parallel with clinical trials for additional accepted therapeutics addressing other pain conditions of high unmet need. EPPIC-Net continues to seek innovative, non-addictive investigational therapeutics ready for early phase clinical trials (IND/IDE ready or approved) for ANY pain condition lacking adequate treatment. Proposed therapeutics can include novel drugs, small molecules, biologics, natural products, and devices, as well as repurposed drugs or devices. Applications from academia, industry, and not-for-profit organizations, worldwide, can be submitted at any time and are reviewed on a rolling basis. In concert with the NIH HEAL Initiative, the NINDS established the Early Phase Pain Investigation Clinical Network (EPPIC-Net) to accelerate clinical trials of non-addictive pharmacologic/non-pharmacologic therapeutics (“assets”) for pain conditions of high unmet need. We present EPPIC-Net's accomplishments since opening in Q4 of 2019. In its first year, EPPIC-Net established a robust infrastructure including a Clinical Coordinating Center, Data Coordinating Center, and 12 Specialized Clinical Centers across the US, providing broad outreach to diverse pain populations. For accepted assets, EPPIC-Net delivers a collaborative network of multi-disciplinary pain experts who provide novel early phase clinical trial design, incorporating proof-of-concept testing and biomarker validation, study conduct, and data analysis. NINDS utilizes a unique, rigorous, 3-stage application/review process, with trials funded under NIH's “Other Transactions” Authority. For accepted assets, trials are run by the NIH-funded network, at no cost to asset providers who provide clinical grade asset for the trial. Asset owners retain intellectual property rights to their asset. In its first two years of operation, EPPIC-Net funded clinical trials for three assets. The first trial, focused on painful knee osteoarthritis, is open to enrollment. Start-up activities are underway for the others. The latter two trials will be conducted under an innovative master platform protocol for painful diabetic peripheral neuropathy. The master protocol will run in parallel with clinical trials for additional accepted therapeutics addressing other pain conditions of high unmet need. EPPIC-Net continues to seek innovative, non-addictive investigational therapeutics ready for early phase clinical trials (IND/IDE ready or approved) for ANY pain condition lacking adequate treatment. Proposed therapeutics can include novel drugs, small molecules, biologics, natural products, and devices, as well as repurposed drugs or devices. Applications from academia, industry, and not-for-profit organizations, worldwide, can be submitted at any time and are reviewed on a rolling basis." @default.
• W4229058277 created "2022-05-08" @default.
• W4229058277 creator A5033291833 @default.
• W4229058277 creator A5043333656 @default.
• W4229058277 creator A5044706338 @default.
• W4229058277 creator A5071530216 @default.
• W4229058277 creator A5081298166 @default.
• W4229058277 date "2022-05-01" @default.
• W4229058277 modified "2023-09-28" @default.
• W4229058277 title "Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, and NINDS (National Institute of Neurological Disorders and Stroke) Early Phase Pain Investigation Clinical Network (EPPIC-Net) Provides Robust Infrastructure for Clinical Trials of Non-addictive Pain Therapeutics" @default.
• W4229058277 doi "https://doi.org/10.1016/j.jpain.2022.03.123" @default.
• W4229058277 hasPublicationYear "2022" @default.
• W4229058277 type Work @default.
• W4229058277 citedByCount "0" @default.
• W4229058277 crossrefType "journal-article" @default.
• W4229058277 hasAuthorship W4229058277A5033291833 @default.
• W4229058277 hasAuthorship W4229058277A5043333656 @default.
• W4229058277 hasAuthorship W4229058277A5044706338 @default.
• W4229058277 hasAuthorship W4229058277A5071530216 @default.
• W4229058277 hasAuthorship W4229058277A5081298166 @default.
• W4229058277 hasBestOaLocation W42290582771 @default.
• W4229058277 hasConcept C118552586 @default.
• W4229058277 hasConcept C142724271 @default.
• W4229058277 hasConcept C204787440 @default.
• W4229058277 hasConcept C2780385302 @default.
• W4229058277 hasConcept C38652104 @default.
• W4229058277 hasConcept C41008148 @default.
• W4229058277 hasConcept C48856860 @default.
• W4229058277 hasConcept C535046627 @default.
• W4229058277 hasConcept C71924100 @default.
• W4229058277 hasConcept C76178495 @default.
• W4229058277 hasConceptScore W4229058277C118552586 @default.
• W4229058277 hasConceptScore W4229058277C142724271 @default.
• W4229058277 hasConceptScore W4229058277C204787440 @default.
• W4229058277 hasConceptScore W4229058277C2780385302 @default.
• W4229058277 hasConceptScore W4229058277C38652104 @default.
• W4229058277 hasConceptScore W4229058277C41008148 @default.
• W4229058277 hasConceptScore W4229058277C48856860 @default.
• W4229058277 hasConceptScore W4229058277C535046627 @default.
• W4229058277 hasConceptScore W4229058277C71924100 @default.
• W4229058277 hasConceptScore W4229058277C76178495 @default.
• W4229058277 hasIssue "5" @default.
• W4229058277 hasLocation W42290582771 @default.
• W4229058277 hasOpenAccess W4229058277 @default.
• W4229058277 hasPrimaryLocation W42290582771 @default.
• W4229058277 hasRelatedWork W119712210 @default.
• W4229058277 hasRelatedWork W1996710384 @default.
• W4229058277 hasRelatedWork W2041040845 @default.
• W4229058277 hasRelatedWork W2367218952 @default.
• W4229058277 hasRelatedWork W2414662763 @default.
• W4229058277 hasRelatedWork W2418602632 @default.
• W4229058277 hasRelatedWork W2577645892 @default.
• W4229058277 hasRelatedWork W4211089529 @default.
• W4229058277 hasRelatedWork W4367318326 @default.
• W4229058277 hasRelatedWork W4385418293 @default.
• W4229058277 hasVolume "23" @default.
• W4229058277 isParatext "false" @default.
• W4229058277 isRetracted "false" @default.
• W4229058277 workType "article" @default.